ArticleBlood advances2021

In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported.

Tauangtham Anekpuritanang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.